Hjem › Tripelnegativ brystkreft › Michigan › Grand Rapids
Kliniske studier for Tripelnegativ brystkreft i Grand Rapids, MI
15 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Grand Rapids (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekruttererFase 1/2
- BAMF Health, Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruttererFase 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
RekruttererFase 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekruttererFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekruttererFase 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- START Midwest /ID# 248685, Grand Rapids
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Grand Rapids
- Ikke-småcellet lungekreft44 studier
- Kolorektal kreft40 studier
- Kreft (alle typer)28 studier
- Brystkreft26 studier
- Eggstokkreft24 studier
- Metastatisk kreft22 studier
- Prostatakreft19 studier
- Endometriekreft18 studier
- Mavekreft18 studier
- Pankreaskreft18 studier
- Melanom17 studier
- Plateepitelcancer i hode og hals15 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.